This Psychedelic Therapy Just Cured Depression and Is Going Mainstream | Dr Ben Miles

The Gist

Pharmaceutical giant Eli Lilly acquired AtaiBeckley for 2.8 billion dollars to secure BPL-003, a synthetic psychedelic nasal spray derived from 5-MeO-DMT that treats treatment-resistant depression in a 90-minute session without requiring psychotherapy.

Quick Overview

Eli Lilly purchased AtaiBeckley for 2.8 billion dollars to commercialize BPL-003, a synthetic 5-MeO-DMT nasal spray that provides rapid antidepressant effects without the traditional multi-hour psychotherapy sessions and high anxiety side effects seen in older psychedelics. Clinical trials demonstrate durable depression symptom reductions comparable to psilocybin and MDMA therapies, but with vastly shorter administration times and scalable delivery models.

Key Points: Eli Lilly paid 2.8 billion dollars upfront with an additional 1 billion dollars in milestones to acquire AtaiBeckley in mid-2025. BPL-003 is a synthetic formulation of 5-MeO-DMT derived from the Sonoran Desert toad, administered via a transmucosal nasal spray. Phase 2b clinical trials for BPL-003 showed that a single 12-milligram dose reduced Montgomery-Åsberg depression scores by 11 points at week four. Patients achieved discharge readiness within 90 minutes of administration, eliminating the need for full-day clinic stays. Unlike psilocybin and LSD which bind primarily to 5-HT2A receptors, 5-MeO-DMT also strongly targets 5-HT1A receptors in the hippocampus and prefrontal cortex for a more internal introspective experience. AtaiBeckley achieved FDA Breakthrough Therapy Designation for BPL-003 in late 2024 following successful trial results. Traditional antidepressant medications typically improve depression scores by only 3 points compared to placebos even after weeks of daily dosing.

Context: Psychedelic compounds such as psilocybin, LSD, and MDMA have shown immense promise in clinical trials for treating severe psychiatric conditions like major depressive disorder and post-traumatic stress disorder, but historical barriers including lengthy administration times, unblinding challenges during clinical trials, and regulatory hurdles have prevented widespread medical adoption until now.